Hypomethylating agents for patients with myelodysplastic syndrome

  • Protocol
  • Intervention

Authors

  • Kathrin Bauer,

    Corresponding author
    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    • Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. kathrin.bauer@uk-koeln.de.

    Search for more papers by this author
  • Franz Hutzschenreuter,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Nicole Skoetz,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Karl-Anton Kreuzer,

    1. University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Ina Monsef,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Andreas Engert

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this systematic review is to evaluate the role of hypomethylating agents (that is 5-Aza, DAC) for patients with MDS. For this purpose we will critically, systematically and statistically analyse the efficacy of hypomethylating agents compared to best supportive care or no treatment as well as to other agents or chemotherapy regimens with regard to overall survival (OS), treatment-related mortality (TRM), complete response rate (CR), progression-free survival (PFS) or similar outcomes, quality of life, adverse events and the time to transformation to AML.